BridgeBio Pharma, Inc. (BBIO)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about BridgeBio Pharma, Inc. (BBIO)
Go deeper and ask any question about BBIO
Company Performance
Current Price
as of Sep 18, 2024$25.96
P/E Ratio
N/A
Market Cap
$4.88B
Description
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.
Metrics
Overview
- HQPalo Alto, CA
- SectorHealth Technology
- IndustryBiotechnology
- TickerBBIO
- Price$25.96-2.88%
Trading Information
- Market Cap$4.88B
- Float75.05%
- Average Daily Volume (1m)2,597,991
- Average Daily Volume (3m)2,197,744
- EPS-$2.64
Company
- Revenue$219.12M
- Rev Growth (1yr)32.11%
- Net Income-$73.46M
- Gross Margin13.65%
- EBITDA Margin-7,890.87%
- EBITDA-$171.07M
- EV$5.90B
- EV/Revenue26.95
- P/EN/A
- P/S22.22
Documents
SEC Filings
Factset Street Account
Factset